Shanghai MicuRx Pharmaceutical Co., Ltd. (SHA:688373)
China flag China · Delayed Price · Currency is CNY
6.25
+0.13 (2.12%)
Feb 3, 2026, 4:00 PM EST

SHA:688373 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
136.7130.2790.7848.217.66-
Revenue Growth (YoY)
13.85%43.51%88.31%529.33%--
Cost of Revenue
20.7922.4116.78.820.76-
Gross Profit
115.91107.8774.0839.386.9-
Selling, General & Admin
160.31176.79168.57146.18124.3842.09
Research & Development
297.07368.56344.86150.39151.7653.03
Other Operating Expenses
-0.320.410.30.140.030.35
Operating Expenses
457.87546.53514.06296.9276.295.46
Operating Income
-341.97-438.66-439.98-257.52-269.3-95.46
Interest Expense
-11.61-11.15-10.14-8.82-5.23-2.44
Interest & Investment Income
2.642.372.194.42.391
Currency Exchange Gain (Loss)
-4.52-4.520.02-5.59-0.29-0
Other Non Operating Income (Expenses)
0.49-1-0.130.34-0.4-0.03
EBT Excluding Unusual Items
-354.97-452.96-448.03-267.19-272.82-96.93
Gain (Loss) on Sale of Investments
11.317.0833.3418.4910.53-0.14
Gain (Loss) on Sale of Assets
0.030.0300.49-0.02-0
Asset Writedown
------0.01
Other Unusual Items
0.851.34-0.4627.9236.0810.76
Pretax Income
-342.78-434.51-415.15-220.29-226.23-86.32
Income Tax Expense
0.186.215.970.010.040.01
Net Income
-342.96-440.72-421.12-220.3-226.27-86.33
Net Income to Common
-342.96-440.72-421.12-220.3-226.27-86.33
Shares Outstanding (Basic)
643656656580526255
Shares Outstanding (Diluted)
643656656580526255
Shares Change (YoY)
-2.08%-13.09%10.17%106.16%12.82%
EPS (Basic)
-0.53-0.67-0.64-0.38-0.43-0.34
EPS (Diluted)
-0.53-0.67-0.64-0.38-0.43-0.34
Free Cash Flow
-320.82-448.1-336.74-252.18-203.89-90.14
Free Cash Flow Per Share
-0.50-0.68-0.51-0.43-0.39-0.35
Gross Margin
84.79%82.80%81.61%81.70%90.08%-
Operating Margin
-250.17%-336.72%-484.69%-534.19%-3515.62%-
Profit Margin
-250.89%-338.31%-463.91%-456.99%-2953.91%-
Free Cash Flow Margin
-234.70%-343.97%-370.96%-523.13%-2661.81%-
EBITDA
-339.52-436.4-437.97-256.22-268.75-94.99
D&A For EBITDA
2.452.262.021.290.550.47
EBIT
-341.97-438.66-439.98-257.52-269.3-95.46
Revenue as Reported
136.7130.2790.7848.217.66-
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.